SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-063267
Filing Date
2022-10-11
Accepted
2022-10-11 16:16:17
Documents
15
Period of Report
2022-10-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea166940-8k_biotechacq.htm   iXBRL 8-K 35431
2 PROMISSORY NOTE ea166940ex10-1_biotechacq.htm EX-10.1 22943
3 PROMISSORY NOTE ea166940ex10-2_biotechacq.htm EX-10.2 24820
  Complete submission text file 0001213900-22-063267.txt   325954

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE biotu-20221004.xsd EX-101.SCH 4332
5 XBRL DEFINITION FILE biotu-20221004_def.xml EX-101.DEF 27229
6 XBRL LABEL FILE biotu-20221004_lab.xml EX-101.LAB 37732
7 XBRL PRESENTATION FILE biotu-20221004_pre.xml EX-101.PRE 25849
9 EXTRACTED XBRL INSTANCE DOCUMENT ea166940-8k_biotechacq_htm.xml XML 6999
Mailing Address 545 WEST 25TH STREET 20TH FLOOR NEW YORK NY 10001
Business Address 545 WEST 25TH STREET 20TH FLOOR NEW YORK NY 10001 8586920539
Biotech Acquisition Co (Filer) CIK: 0001825413 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39935 | Film No.: 221304258
SIC: 2834 Pharmaceutical Preparations